Brinker Capital Investments, LLC Bei Gene, Ltd. Transaction History

Brinker Capital Investments, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $593,112 - $1.09 Million	-4,048 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$248.56 - $389.34 $33,804 - $52,950	-136 Reduced 3.25%	4,048 $1.1 Million
Q2 2021 Aug 03, 2021	BUY	$292.75 - $367.01 $132,908 - $166,622	454 Added 12.17%	4,184 $1.44 Million
Q1 2021 May 12, 2021	SELL	$260.64 - $382.12 $1.06 Million - $1.55 Million	-4,054 Reduced 52.08%	3,730 $1.3 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $820,838 - $1.17 Million	3,709 Added 91.02%	7,784 $2.01 Million
Q3 2020 Dec 03, 2020	BUY	$189.18 - $286.44 $770,908 - $1.17 Million	4,075 New	4,075 $1.17 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Brinker Capital Investments, LLC with notifications on news.